Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ajuba LIM protein is a versatile scaffold and transcriptional corepressor that regulates cell adhesion, cytoskeletal organization, mitosis, gene transcription, hypoxic response, cell proliferation, differentiation, migration, and apoptosis. It connects membrane and nuclear events, integrating diverse signaling pathways such as Hippo, JAK/STAT, IL-1, and MAPK. Structurally, AJUBA has three C-terminal LIM domains (double zinc fingers) and a proline-rich N-terminal preLIM domain with nuclear export and protein–protein interaction features. AJUBA's aberrant expression or localization participates in EMT, metastasis, and tumor progression, and alters prognosis in many cancer types. Its molecular complexity and involvement in a variety of essential functions make AJUBA both a critical biological regulator and a challenging, but potentially valuable, therapeutic target.
For hypothetical drugs targeting AJUBA: Inhibition of its scaffolding or adaptor function; Disruption of AJUBA-dependent protein complexes; Modulation of Hippo pathway activity (e.g., affecting YAP1 phosphorylation); Inhibition of its effect on EMT and metastatic gene expression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ajuba LIM protein (AJUBA).